Alkermes (ALKS) PT Raised to $70 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Alkermes (ALKS) PT Raised to $70 at Credit Suisse
October 21, 2016 9:29 AM EDTCredit Suisse analyst Vamil Divan reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $52.00) after the company released positive data after the close from the third Phase 3 study for their pipeline anti-depression drug ALKS-5461.
Divan... More
Alkermes (ALKS) PT Raised to $70 at Leerink Partners
October 21, 2016 6:41 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $57.00) after the company announced positive results from their third ph3 study for ALKS5461 in depression.
Matteis commented, "We were previously... More
JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78
October 21, 2016 6:35 AM EDTJPMorgan upgraded Alkermes (NASDAQ: ALKS) from Neutral to Overweight with a price target of $78.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $43.51 yesterday.
... MoreAlkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint
October 20, 2016 4:01 PM EDTAlkermes plc (NASDAQ: ALKS) today announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The... More
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
October 20, 2016 4:00 PM EDTAlkermes plc (NASDAQ: ALKS) announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The study... More
